Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02106832




Registration number
NCT02106832
Ethics application status
Date submitted
4/04/2014
Date registered
8/04/2014
Date last updated
2/10/2017

Titles & IDs
Public title
Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Scientific title
Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Secondary ID [1] 0 0
2013-004659-19
Secondary ID [2] 0 0
15626
Universal Trial Number (UTN)
Trial acronym
RESPIRE 2
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Bronchiectasis 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Other respiratory disorders / diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Ciprofloxacin (BAYQ3939) dry powder for inhalation
Treatment: Drugs - Ciprofloxacin (BAYQ3939) dry powder for inhalation
Treatment: Drugs - Placebo
Treatment: Drugs - Placebo

Experimental: Ciprofloxacin DPI 28 Days on/off (Cipro 28) - Subjects received ciprofloxacin (BAYQ3939) 32.5 milligram (mg) corresponding to 50 mg dry powder for inhalation (DPI) administered twice daily (BID) (every 12 hours); a treatment cycle consisted of a 28-day on-treatment phase followed by a 28-day off-treatment phase (48 weeks treatment phase = 6 active cycles).

Experimental: Ciprofloxacin DPI 14 Days on/off (Cipro 14) - Subjects received ciprofloxacin 32.5 mg corresponding to 50 mg DPI administered BID (every 12 hours); a treatment cycle consisted of a 14-day on-treatment phase followed by a 14-day off-treatment phase (48 weeks treatment phase = 12 active cycles).

Placebo comparator: Placebo 28 Days on/off (Placebo 28) - Subjects received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours); a treatment cycle consisted of a 28-day on-treatment phase followed by a 28-day off-treatment phase (48 weeks treatment phase = 6 cycles).

Placebo comparator: Placebo 14 Days on/off (Placebo 14) - Subjects received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours); a treatment cycle consisted of a 14-day on-treatment phase followed by a 14-day off-treatment phase (48 weeks treatment phase = 12 cycles).


Treatment: Drugs: Ciprofloxacin (BAYQ3939) dry powder for inhalation
Ciprofloxacin dry powder for inhalation (DPI) 32.5 mg inhaled twice daily in cycles of 28 days on-treatment and 28 days off-treatment.

Treatment: Drugs: Ciprofloxacin (BAYQ3939) dry powder for inhalation
Ciprofloxacin DPI 32.5 mg inhaled twice daily in cycles of 14 days on-treatment and 14 days off-treatment.

Treatment: Drugs: Placebo
Matching placebo inhaled twice daily intermittently for 28 days on / 28 days off

Treatment: Drugs: Placebo
Matching placebo inhaled twice daily intermittently for 14 days on / 14 days off
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Time to First Exacerbation Event Within 48 Weeks - Cipro 28 vs. Pooled Placebo
Timepoint [1] 0 0
Up to Week 48
Primary outcome [2] 0 0
Time to First Exacerbation Event Within 48 Weeks - Cipro 14 vs. Pooled Placebo
Timepoint [2] 0 0
Up to Week 48
Secondary outcome [1] 0 0
Number of Participants With Exacerbation Events With Worsening of at Least Three Signs/Symptoms Over 48 Weeks
Timepoint [1] 0 0
Up to Week 48
Secondary outcome [2] 0 0
Number of Participants With Exacerbation Events With Worsening of at Least One Sign/Symptom Over 48 Weeks
Timepoint [2] 0 0
Up to Week 48
Secondary outcome [3] 0 0
Percentage of Participants With Pathogen Eradication at End of Treatment (Week 44/46)
Timepoint [3] 0 0
End of treatment (Week 44/46)
Secondary outcome [4] 0 0
Mean Change From Baseline in Patient Reported Outcome Saint George's Respiratory Questionnaire (SGRQ) Symptoms Component Score at End of Treatment (Week 44/46)
Timepoint [4] 0 0
Baseline and end of treatment (Week 44/46)
Secondary outcome [5] 0 0
Percentage of Participants With Occurrence of New Pathogens Present at End of Treatment (Week 44/46)
Timepoint [5] 0 0
End of treatment (Week 44/46)
Secondary outcome [6] 0 0
Mean Change From Baseline in Patient Reported Outcome Quality of Life Questionnaire for Bronchiectasis (QoL-B) Respiratory Symptoms Domain Score at End of Treatment (Week 44/46)
Timepoint [6] 0 0
Baseline and end of treatment (Week 44/46)
Secondary outcome [7] 0 0
Mean Change From Baseline in Forced Expiratory Volume in One Second (FEV1) at End of Treatment (Week 44/46)
Timepoint [7] 0 0
Baseline and end of treatment (Week 44/46)

Eligibility
Key inclusion criteria
* Patients with a proven and documented diagnosis of non CF idiopathic or post infectious bronchiectasis
* Stable pulmonary status and stable regimen of standard treatment at least for the past 4 weeks
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Forced expiratory volume in 1 second (FEV1) <30% or >90% predicted
* Active allergic bronchopulmonary aspergillosis
* Active and actively treated non tuberculosis mycobacterial (NTM) infection or tuberculosis
* Primary diagnosis of Chronic obstructive pulmonary disease (COPD)

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
30/04/2014
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
19/10/2016
Sample size
Target
Accrual to date
Final
521
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC,WA
Recruitment hospital [1] 0 0
- Kogarah
Recruitment hospital [2] 0 0
- New Lambton Heights
Recruitment hospital [3] 0 0
- Adelaide
Recruitment hospital [4] 0 0
- Parkville
Recruitment hospital [5] 0 0
- Murdoch
Recruitment hospital [6] 0 0
- Perth
Recruitment postcode(s) [1] 0 0
2217 - Kogarah
Recruitment postcode(s) [2] 0 0
2305 - New Lambton Heights
Recruitment postcode(s) [3] 0 0
5041 - Adelaide
Recruitment postcode(s) [4] 0 0
5042 - Adelaide
Recruitment postcode(s) [5] 0 0
3050 - Parkville
Recruitment postcode(s) [6] 0 0
6150 - Murdoch
Recruitment postcode(s) [7] 0 0
6009 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Kansas
Country [7] 0 0
United States of America
State/province [7] 0 0
Minnesota
Country [8] 0 0
United States of America
State/province [8] 0 0
New York
Country [9] 0 0
United States of America
State/province [9] 0 0
North Carolina
Country [10] 0 0
United States of America
State/province [10] 0 0
Oregon
Country [11] 0 0
United States of America
State/province [11] 0 0
Pennsylvania
Country [12] 0 0
United States of America
State/province [12] 0 0
South Carolina
Country [13] 0 0
United States of America
State/province [13] 0 0
Texas
Country [14] 0 0
Argentina
State/province [14] 0 0
Ciudad Auton. de Buenos Aires
Country [15] 0 0
Argentina
State/province [15] 0 0
Mendoza
Country [16] 0 0
Argentina
State/province [16] 0 0
Córdoba
Country [17] 0 0
Argentina
State/province [17] 0 0
Vicente López
Country [18] 0 0
Austria
State/province [18] 0 0
Graz
Country [19] 0 0
Austria
State/province [19] 0 0
Salzburg
Country [20] 0 0
Brazil
State/province [20] 0 0
Minas Gerais
Country [21] 0 0
Brazil
State/province [21] 0 0
Pernambuco
Country [22] 0 0
Brazil
State/province [22] 0 0
Rio Grande do Sul
Country [23] 0 0
Brazil
State/province [23] 0 0
Sao Paulo
Country [24] 0 0
Brazil
State/province [24] 0 0
Porto Alegre
Country [25] 0 0
Bulgaria
State/province [25] 0 0
Gabrovo
Country [26] 0 0
Bulgaria
State/province [26] 0 0
Kozloduy
Country [27] 0 0
Bulgaria
State/province [27] 0 0
Lovech
Country [28] 0 0
Bulgaria
State/province [28] 0 0
Razgrad
Country [29] 0 0
Bulgaria
State/province [29] 0 0
Ruse
Country [30] 0 0
Bulgaria
State/province [30] 0 0
Sevlievo
Country [31] 0 0
Bulgaria
State/province [31] 0 0
Sliven
Country [32] 0 0
Bulgaria
State/province [32] 0 0
Sofia
Country [33] 0 0
Bulgaria
State/province [33] 0 0
Stara Zagora
Country [34] 0 0
China
State/province [34] 0 0
Fujian
Country [35] 0 0
China
State/province [35] 0 0
Guangdong
Country [36] 0 0
China
State/province [36] 0 0
Inner Mongolia
Country [37] 0 0
China
State/province [37] 0 0
Jiangsu
Country [38] 0 0
China
State/province [38] 0 0
Jiangxi
Country [39] 0 0
China
State/province [39] 0 0
Liaoning
Country [40] 0 0
China
State/province [40] 0 0
Ningxia
Country [41] 0 0
China
State/province [41] 0 0
Sichuan
Country [42] 0 0
China
State/province [42] 0 0
Beijing
Country [43] 0 0
China
State/province [43] 0 0
Chongqing
Country [44] 0 0
China
State/province [44] 0 0
Shanghai
Country [45] 0 0
Czechia
State/province [45] 0 0
Brno
Country [46] 0 0
Czechia
State/province [46] 0 0
Prague 4
Country [47] 0 0
Czechia
State/province [47] 0 0
Praha 2
Country [48] 0 0
Czechia
State/province [48] 0 0
Praha 8
Country [49] 0 0
Germany
State/province [49] 0 0
Brandenburg
Country [50] 0 0
Germany
State/province [50] 0 0
Hessen
Country [51] 0 0
Germany
State/province [51] 0 0
Niedersachsen
Country [52] 0 0
Germany
State/province [52] 0 0
Nordrhein-Westfalen
Country [53] 0 0
Germany
State/province [53] 0 0
Sachsen
Country [54] 0 0
Germany
State/province [54] 0 0
Thüringen
Country [55] 0 0
Germany
State/province [55] 0 0
Berlin
Country [56] 0 0
Germany
State/province [56] 0 0
Hamburg
Country [57] 0 0
Hong Kong
State/province [57] 0 0
Hong Kong
Country [58] 0 0
Hong Kong
State/province [58] 0 0
Kowloon
Country [59] 0 0
Hong Kong
State/province [59] 0 0
New Territories
Country [60] 0 0
Hong Kong
State/province [60] 0 0
Shatin
Country [61] 0 0
Korea, Republic of
State/province [61] 0 0
Daejeon Gwang''yeogsi
Country [62] 0 0
Korea, Republic of
State/province [62] 0 0
Gyeonggido
Country [63] 0 0
Korea, Republic of
State/province [63] 0 0
Incheon Gwang''yeogsi
Country [64] 0 0
Korea, Republic of
State/province [64] 0 0
Seoul Teugbyeolsi
Country [65] 0 0
Korea, Republic of
State/province [65] 0 0
Daegu
Country [66] 0 0
Korea, Republic of
State/province [66] 0 0
Incheon
Country [67] 0 0
Korea, Republic of
State/province [67] 0 0
Seoul
Country [68] 0 0
Latvia
State/province [68] 0 0
Daugavpils
Country [69] 0 0
Latvia
State/province [69] 0 0
Jurmala
Country [70] 0 0
Latvia
State/province [70] 0 0
Kraslava
Country [71] 0 0
Latvia
State/province [71] 0 0
Riga
Country [72] 0 0
Latvia
State/province [72] 0 0
Talsi
Country [73] 0 0
Lithuania
State/province [73] 0 0
Klaipeda
Country [74] 0 0
Lithuania
State/province [74] 0 0
Vilnius
Country [75] 0 0
Netherlands
State/province [75] 0 0
Alkmaar
Country [76] 0 0
Netherlands
State/province [76] 0 0
Assen
Country [77] 0 0
Netherlands
State/province [77] 0 0
Groningen
Country [78] 0 0
Netherlands
State/province [78] 0 0
Helmond
Country [79] 0 0
Netherlands
State/province [79] 0 0
Maastricht
Country [80] 0 0
Netherlands
State/province [80] 0 0
Sittard-Geleen
Country [81] 0 0
Netherlands
State/province [81] 0 0
Veldhoven
Country [82] 0 0
Philippines
State/province [82] 0 0
City of San Fernando
Country [83] 0 0
Philippines
State/province [83] 0 0
Manila
Country [84] 0 0
Philippines
State/province [84] 0 0
Quezon City
Country [85] 0 0
Poland
State/province [85] 0 0
Bielsko-Biala
Country [86] 0 0
Poland
State/province [86] 0 0
Czestochowa
Country [87] 0 0
Poland
State/province [87] 0 0
Gorzow Wielkopolski
Country [88] 0 0
Poland
State/province [88] 0 0
Grudziadz
Country [89] 0 0
Poland
State/province [89] 0 0
Katowice
Country [90] 0 0
Poland
State/province [90] 0 0
Kielce
Country [91] 0 0
Poland
State/province [91] 0 0
Krakow
Country [92] 0 0
Poland
State/province [92] 0 0
Ksawerow
Country [93] 0 0
Poland
State/province [93] 0 0
Mrozy
Country [94] 0 0
Poland
State/province [94] 0 0
Ostrowiec Swietokrzyski
Country [95] 0 0
Poland
State/province [95] 0 0
Rzeszow
Country [96] 0 0
Poland
State/province [96] 0 0
Warszawa
Country [97] 0 0
Portugal
State/province [97] 0 0
Porto
Country [98] 0 0
Portugal
State/province [98] 0 0
Região Autónoma dos Açores
Country [99] 0 0
Portugal
State/province [99] 0 0
Faro
Country [100] 0 0
Portugal
State/province [100] 0 0
Lisboa
Country [101] 0 0
Romania
State/province [101] 0 0
Bragadiru
Country [102] 0 0
Romania
State/province [102] 0 0
Brasov
Country [103] 0 0
Romania
State/province [103] 0 0
Bucharest
Country [104] 0 0
Romania
State/province [104] 0 0
Codlea
Country [105] 0 0
Romania
State/province [105] 0 0
Constanta
Country [106] 0 0
Romania
State/province [106] 0 0
Iasi
Country [107] 0 0
Romania
State/province [107] 0 0
Ploiesti
Country [108] 0 0
Romania
State/province [108] 0 0
Timisoara
Country [109] 0 0
Russian Federation
State/province [109] 0 0
Arkhangelsk
Country [110] 0 0
Russian Federation
State/province [110] 0 0
Chelyabinsk
Country [111] 0 0
Russian Federation
State/province [111] 0 0
Moscow
Country [112] 0 0
Russian Federation
State/province [112] 0 0
Nizhny Novgorod
Country [113] 0 0
Russian Federation
State/province [113] 0 0
Novosibirsk
Country [114] 0 0
Russian Federation
State/province [114] 0 0
St. Petersburg
Country [115] 0 0
Russian Federation
State/province [115] 0 0
Tomsk
Country [116] 0 0
Russian Federation
State/province [116] 0 0
Ufa
Country [117] 0 0
Russian Federation
State/province [117] 0 0
Voronezh
Country [118] 0 0
Russian Federation
State/province [118] 0 0
Yaroslavl
Country [119] 0 0
Serbia
State/province [119] 0 0
Belgrade
Country [120] 0 0
Serbia
State/province [120] 0 0
Cacak
Country [121] 0 0
Serbia
State/province [121] 0 0
Knez Selo
Country [122] 0 0
Serbia
State/province [122] 0 0
Kragujevac
Country [123] 0 0
Serbia
State/province [123] 0 0
Sombor
Country [124] 0 0
Serbia
State/province [124] 0 0
Sremska Kamenica
Country [125] 0 0
Serbia
State/province [125] 0 0
Valjevo
Country [126] 0 0
Slovakia
State/province [126] 0 0
Bratislava
Country [127] 0 0
Slovakia
State/province [127] 0 0
Presov
Country [128] 0 0
South Africa
State/province [128] 0 0
Gauteng
Country [129] 0 0
South Africa
State/province [129] 0 0
Kwazulu-Natal
Country [130] 0 0
South Africa
State/province [130] 0 0
Western Cape
Country [131] 0 0
Taiwan
State/province [131] 0 0
Chiayi
Country [132] 0 0
Taiwan
State/province [132] 0 0
Kaohsiung
Country [133] 0 0
Taiwan
State/province [133] 0 0
New Taipei City,
Country [134] 0 0
Taiwan
State/province [134] 0 0
Taichung
Country [135] 0 0
Taiwan
State/province [135] 0 0
Taipei
Country [136] 0 0
Thailand
State/province [136] 0 0
Bangkok
Country [137] 0 0
Thailand
State/province [137] 0 0
Chiangmai
Country [138] 0 0
Thailand
State/province [138] 0 0
Khon Kaen
Country [139] 0 0
Thailand
State/province [139] 0 0
NakhonRatchasima
Country [140] 0 0
Thailand
State/province [140] 0 0
Phitsanulok
Country [141] 0 0
Thailand
State/province [141] 0 0
Udonthani
Country [142] 0 0
Turkey
State/province [142] 0 0
Ankara
Country [143] 0 0
Turkey
State/province [143] 0 0
Balcali
Country [144] 0 0
Turkey
State/province [144] 0 0
Izmir
Country [145] 0 0
Turkey
State/province [145] 0 0
Kampus
Country [146] 0 0
Turkey
State/province [146] 0 0
Konya
Country [147] 0 0
Turkey
State/province [147] 0 0
Maltepe
Country [148] 0 0
Turkey
State/province [148] 0 0
Mersin
Country [149] 0 0
Turkey
State/province [149] 0 0
Pendik
Country [150] 0 0
Turkey
State/province [150] 0 0
Samsun
Country [151] 0 0
Turkey
State/province [151] 0 0
Sehitkamil

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Bayer
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Novartis
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to evaluate if the time to first pulmonary exacerbation of bronchiectasis or its frequency can be prolonged by inhalation of ciprofloxacin for 28 days every other 28 days or for 14 days every other 14 days over 48 weeks.
Trial website
https://clinicaltrials.gov/study/NCT02106832
Trial related presentations / publications
Aksamit T, De Soyza A, Bandel TJ, Criollo M, Elborn JS, Operschall E, Polverino E, Roth K, Winthrop KL, Wilson R. RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. Eur Respir J. 2018 Jan 25;51(1):1702053. doi: 10.1183/13993003.02053-2017. Print 2018 Jan.
Aksamit T, Bandel TJ, Criollo M, De Soyza A, Elborn JS, Operschall E, Polverino E, Roth K, Winthrop KL, Wilson R. The RESPIRE trials: Two phase III, randomized, multicentre, placebo-controlled trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis. Contemp Clin Trials. 2017 Jul;58:78-85. doi: 10.1016/j.cct.2017.05.007. Epub 2017 May 8.
Public notes

Contacts
Principal investigator
Name 0 0
Bayer Study Director
Address 0 0
Bayer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02106832